Jeremiah B. Frueauf is a director in Sterne Kessler’s Biotechnology/Chemical Practice Group. Jeremiah counsels domestic and international clients on patent procurement, product development and clearance strategies, and protection of complex worldwide patent portfolios. Jeremiah leverages his experience in numerous inter partes disputes, including district court litigation, USPTO litigation (inter partes reviews and post-grant reviews), and Section 337 investigations before the USITC to help patent owners and challengers craft and execute patent strategies that best align with their business needs
Jeremiah counsels clients across the life sciences spectrum, from small and large molecule development, to bio-based products for the bioeconomy, to personalized medicine, diagnostics, and biosensors. His clients span from early-stage start-ups and SMEs to multinational corporations, and he is frequently sought after to provide strategic advice to support clients’ product development—from conception to launch.
He is a contributing author of Patent Office Litigation, a two-volume set focused on the new contested proceedings under the America Invents Act published in 2012 by Thomson Reuters Westlaw. This book examines how the proceedings interact with other aspects of patent procurement and enforcement, and delivers practical analysis and advice.
Prior to joining Sterne Kessler, Jeremiah was a Biologist at the National Cancer Institute where he studied the molecular signaling pathways related to programmed cell death using various molecular, biochemical, and proteomic technologies. He also assisted in the administration of phase II clinical trials related to an ovarian cancer therapeutic.
Jeremiah's graduate work at Michigan State University as a member of the Starch Bio-Engineering Group focused on analysis of the structure/function relationships of the enzymes involved in starch and glycogen biosynthesis. His work included successful alteration of the catalytic activity and inhibitor specificities of these enzymes to affect the recombinant production of starch or glycogen molecules.
Jeremiah received his J.D. from the Georgetown University Law Center, his M.S. in biochemistry from Michigan State University, and his B.S. in chemistry/biochemistry, summa cum laude, from Ohio University.
- Frueauf J. B., Ballicora M. A., and Preiss J. (2003) “ADP-glucose Pyrophosphorylase from Potato Tuber. Site-Directed Mutagenesis of Homologous Aspartic Acid Residues in the Small and Large Subunits” Plant J. 33: 503-11.
- Frueauf J. B., Ballicora M. A., and Preiss J. (2002) “Alteration of Inhibitor Selectivity by Site-Directed Mutagenesis of Arg294 in the ADP-glucose Pyrophosphorylase from Anabaena PCC 7120” Arch. Biochem. Biophys. 400: 208-14.
- Frueauf J. B., Ballicora M. A., and Preiss J. (2001) “Aspartate Residue 142 is Important for Catalysis by ADP-glucose Pyrophosphorylase from Escherichia coli”J. Biol. Chem. 276: 46319- 25.
- Ballicora M. A., Frueauf J. B., Fu Y. B., Schurmann P., and Preiss J. (2000) “Activation of the Potato Tuber ADP-glucose Pyrophosphorylase by Thioredoxin” J. Biol. Chem. 275: 1315-20.
Law Review Articles
- Jeremiah B. Frueauf, "A Comparison of Section 337 Decisions at the ITC and Parallel District Court Proceedings: The Commission's Decisions Affect Dispositions at the District Courts," Vol. XXII 337 Rep., ITC Trial Law. Ass'n, 4th Ann. Summer Associate Edition 31 (2006).
- Jeremiah B. Frueauf, Note, "Making Your Business Fly Above Section 183: Fair Skies Following Rabinowitz v. Commissioner," 59 Tax Law. 887 (2006).
- Bisnow, "Trending 40 Lawyers Under 40" (2016)